Zura Bio AI Stock Analysis
Zura Bio (94E) AI Stock Analysis
Zura Bio
(Frankfurt:94E)
No summary available
Zura Bio (94E) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 119.44M
- Dividend Yield
- ―
- Average Volume (3M)
- 810
- Price to Earnings (P/E)
- -1.1
- Beta (1Y)
- 0.91
- Revenue Growth
- ―
- EPS Growth
- -68.00%
- Country
- Germany
- Employees
- 40
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Zura Bio Business Overview & Revenue Model
Company Description
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα...
Zura Bio Risk Analysis
Zura Bio disclosed 82 risk factors in its most recent earnings report. Zura Bio reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksZura Bio Peers Comparison
Overall Rating
PBYI64Neutral
VOR44.8Neutral
CLLS44Neutral
PRQR42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | $401.70M | 16.32 | 17.52% | ― | 9.35% | -37.15% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $1.19B | 0.06 | -830.38% | ― | ― | ― | |
| 44Neutral | $84.18M | -1.78 | -94.14% | ― | -0.11% | -13.99% | |
| 42Neutral | $198.98M | -3.23 | -68.44% | ― | 19.49% | -4.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:94E | Zura Bio Limited | 1.12 | -2.38 | -68.00% | |
| PBYI | Puma Biotechnology | 7.77 | 2.81 | 56.65% | |
| PRQR | ProQR Therapeutics BV | 1.41 | -0.64 | -31.22% | |
| CLLS | Cellectis S.A. | 1.18 | -2.96 | -71.50% | |
| VOR | Vor Biopharma, Inc. | 19.42 | 9.40 | 93.81% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
